WallStSmart

AbbVie Inc (ABBV)vsFortress Biotech Inc (FBIO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 96577% more annual revenue ($61.16B vs $63.26M). FBIO leads profitability with a 10.8% profit margin vs 6.9%. ABBV earns a higher WallStSmart Score of 63/100 (C+).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.7Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

FBIO

Hold

37

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-29.3%)

Margin of Safety

-29.3%

Fair Value

$163.42

Current Price

$203.89

$40.47 premium

UndervaluedFair: $163.42Overvalued
FBIOUndervalued (+78.0%)

Margin of Safety

+78.0%

Fair Value

$16.68

Current Price

$2.30

$14.38 discount

UndervaluedFair: $16.68Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$360.63B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.4810/10

Growing faster than its price suggests

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
34.1%10/10

Strong operational efficiency at 34.1%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$4.89B8/10

Generating 4.9B in free cash flow

FBIO1 strengths · Avg: 10.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
6.9%3/10

6.9% margin — thin

P/E RatioValuation
100.0x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-88.7%2/10

Earnings declined 88.7%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

FBIO4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$75.03M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-108.7%2/10

ROE of -108.7% — below average capital efficiency

Free Cash FlowQuality
$-12.54M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.

Bull Case : FBIO

The strongest argument for FBIO centers on Price/Book.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.

Bear Case : FBIO

The primary concerns for FBIO are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

FBIO carries more volatility with a beta of 1.45 — expect wider price swings.

ABBV is growing revenue faster at 10.0% — sustainability is the question.

ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABBV scores higher overall (63/100 vs 37/100). FBIO offers better value entry with a 78.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Fortress Biotech Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.

Want to dig deeper into these stocks?